{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary-progressive+Multiple+Sclerosis&page=2",
    "query": {
      "condition": "Primary-progressive Multiple Sclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary-progressive+Multiple+Sclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T20:35:23.412Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01982942",
      "title": "Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "ibudilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 255,
      "start_date": "2013-11",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Davis, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01982942"
    },
    {
      "nct_id": "NCT05974852",
      "title": "Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 732,
      "start_date": "2023-10-01",
      "completion_date": "2023-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05974852"
    },
    {
      "nct_id": "NCT04943289",
      "title": "Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "DUOC-01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joanne Kurtzberg, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-01-24",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04943289"
    },
    {
      "nct_id": "NCT03493841",
      "title": "Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis",
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Alpha Lipoic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rebecca Spain",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-08",
      "completion_date": "2019-01-25",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03493841"
    },
    {
      "nct_id": "NCT03283826",
      "title": "Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ATA188",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atara Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 134,
      "start_date": "2017-10-19",
      "completion_date": "2024-01-17",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283826"
    },
    {
      "nct_id": "NCT01466114",
      "title": "Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis",
        "Secondary-progressive Multiple Sclerosis",
        "Primary-progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "estriol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Norethindrone",
          "type": "DRUG"
        },
        {
          "name": "Progestin Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 64,
      "start_date": "2011-10",
      "completion_date": "2022-04",
      "has_results": false,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01466114"
    },
    {
      "nct_id": "NCT03983681",
      "title": "Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Strategy-Based Training to Enhance Memory (STEM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo control exercises",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 81,
      "start_date": "2019-09-26",
      "completion_date": "2025-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 2,
      "location_summary": "East Hanover, New Jersey • Marlton, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03983681"
    },
    {
      "nct_id": "NCT03094364",
      "title": "Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis",
        "Hemiparesis"
      ],
      "interventions": [
        {
          "name": "Gaming CI Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Massachusetts, Lowell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-11",
      "completion_date": "2018-10-31",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03094364"
    },
    {
      "nct_id": "NCT04548999",
      "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 769,
      "start_date": "2020-12-03",
      "completion_date": "2027-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 24,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04548999"
    },
    {
      "nct_id": "NCT07067463",
      "title": "A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis (MS) Primary Progressive"
      ],
      "interventions": [
        {
          "name": "Orelabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zenas BioPharma (USA), LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 705,
      "start_date": "2026-03-23",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-07-22T20:35:23.412Z",
      "location_count": 14,
      "location_summary": "Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 11 more",
      "locations": [
        {
          "city": "Pheonix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07067463"
    }
  ]
}